Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

TBPH Interest Expense

Cost of servicing the company's debt during the period.

Theravance Biopharma, Inc.NASDAQ: TBPH

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was $0, compared with $643K a year earlier. Trailing-twelve-month interest expense was $1.82M. Over 3 fiscal years it compounded at -27.2% a year.

Context

  • Interest expense amounted to 2.3% of revenue in FY2025, down 1.7 pp from a year earlier.
  • Interest expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $454.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$2.46M-3.3% YoY
LTMMar 2026
$1.82M-28.9% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-3.3%——
3-year CAGR-27.2%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
2.46M USD
Year-over-year change
-3.3%
4-year CAGR
-26.7%

Interest Expense vs competitors

How TBPH compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -28.9% is the lowest of 4, against a peer median of +35.8%.
  • Interest expense amounts to 1.7% of revenue for TBPH, versus a peer median of 0.0%.
TBPH Competitors
Interest Expense for TBPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VALNValneva SELTM Mar 2026€41.01M EUR+78.9%+30.0%26.2%
GERNGeron CorporationLTM Mar 2026$31.6M USD+35.8%+68.0%16.1%
REPLReplimune Group, Inc.LTM Dec 2025$6.48M USD-17.5%+52.6%—
TBPHTheravance Biopharma, Inc.LTM Mar 2026$1.82M USD-28.9%-27.2%1.7%
VIRVir Biotechnology, Inc.LTM Mar 2026$0 USD——0.0%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
TYRATyra Biosciences, Inc.LTM Mar 2026$0 USD———
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
LENZLENZ Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding TBPH) —+35.8%+52.6%0.0%

Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.31M51.35M57.42M64.38M107.46M
Cost of Revenue193.66M63.39M40.62M37.64M5.52M
Gross Profit(138.35M)(12.05M)16.8M26.74M101.95M
Gross Margin-250.1%-23.5%29.3%41.5%94.9%
Research & Development201.55M70.07M46.34M38.05M37.41M
Selling, General & Admin99.3M67.07M70.45M69.17M73.65M
Operating Expenses119.44M79.91M72.84M73.69M115.2M
Depreciation & Amortization4.81M3.04M2M3.62M5.52M
EBITDA(232.83M)(76.08M)(51.65M)(38.45M)137.22M
EBITDA Margin-420.9%-148.2%-89.9%-59.7%127.7%
Operating Income(257.78M)(91.96M)(56.04M)(46.95M)(13.25M)
Operating Margin-466.1%-179.1%-97.6%-72.9%-12.3%
Interest Income1.11M8.55M9.12M4.88M0
Interest Expense8.55M6.37M2.35M2.55M2.46M
Other Income / Expenses(7.44M)(858K)6.77M2.34M142.49M
Income Before Tax(265.22M)(92.82M)(49.27M)(44.61M)129.25M
Pre-Tax Margin-479.5%-180.8%-85.8%-69.3%120.3%
Income Tax Expense(151K)9K5.92M11.8M23.35M
Net Income(199.43M)872.13M(55.19M)(56.42M)105.9M
Net Margin-360.6%1698.5%-96.1%-87.6%98.5%
EPS (Basic)(2.87)(1.26)(1.00)(1.15)2.10
EPS (Diluted)(2.87)(1.26)(1.00)(1.15)2.06
Weighted Avg Shares69.46M73.59M55.3M48.85M50.32M
Weighted Avg Shares (Diluted)69.46M73.59M55.3M48.85M51.51M

Theravance Biopharma, Inc.

NASDAQ:TBPH

Intrinsic Alpha fair value

Locked

Current Price

$17.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.